Vaxart (Nasdaq:VXRT) - Stock Price, News & Analysis

VXRT Stock Overview

A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform.

About the company

VXRT fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 48.01% per year

Risk Analysis

Has less than 1 year of cash runway

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months compared to the US market

Vaxart, Inc. Competitors

Ocugen

NasdaqCM:OCGN

US$273.5m

Compugen

NasdaqCM:CGEN

US$146.8m

Artiva Biotherapeutics

NasdaqGM:ARTV

US$289.0m

Adaptimmune Therapeutics

NasdaqGS:ADAP

US$212.3m

Price History & Performance

Summary of all time highs, changes and price drops for Vaxart
Historical stock prices
Current Share Price	US$0.71
52 Week High	US$1.54
52 Week Low	US$0.52
Beta	0.67
11 Month Change	-12.71%
3 Month Change	12.08%
1 Year Change	-6.87%
33 Year Change	-89.33%
5 Year Change	108.32%
Change since IPO	-91.69%

There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

Aug 20

Recent updates

There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

Aug 20

An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Jun 15

Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2

Jul 20

Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success

Jul 07

Vaxart: A Unique Vaccine Concern

Jun 14

Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform

Feb 26

Vaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow

Dec 09

Vaxart: Differentiated Covid Oral Route Remains Viable

Nov 16

Vaxart: A Close Look At Their COVID-19 Oral Tablet Vaccine Program

Oct 30

Vaxart: An Update

Oct 02

Companies Like Vaxart (NASDAQ:VXRT) Are In A Position To Invest In Growth

Aug 25

Shareholder Returns

	VXRT	US Biotechs	US Market
7D	-10.0%	1.6%	2.3%
1Y	-6.9%	23.6%	35.1%

Return vs Industry: VXRT underperformed the US Biotechs industry which returned 23.6% over the past year.

Return vs Market: VXRT underperformed the US Market which returned 35.1% over the past year.

Price Volatility

Is VXRT's price volatile compared to industry and market?
VXRT volatility
VXRT Average Weekly Movement	12.0%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

Stable Share Price: VXRT's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: VXRT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
n/a	109	Steven Lo	vaxart.com

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral.

Vaxart, Inc. Fundamentals Summary

How do Vaxart's earnings and revenue compare to its market cap?
VXRT fundamental statistics
Market cap	US$166.46m
Earnings (TTM)	-US$75.66m
Revenue (TTM)	US$13.93m

11.5x

P/S Ratio

-2.1x

P/E Ratio

Is VXRT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VXRT income statement (TTM)
Revenue	US$13.93m
Cost of Revenue	US$66.20m
Gross Profit	-US$52.27m
Other Expenses	US$23.39m
Earnings	-US$75.66m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.33
Gross Margin	-375.30%
Net Profit Margin	-543.21%
Debt/Equity Ratio	5.3%

How did VXRT perform over the long term?

See historical performance and comparison

VXRT Stock Overview

Rewards

Risk Analysis

Vaxart, Inc. Competitors

NasdaqCM:OCGN

US$273.5m

NasdaqCM:CGEN

US$146.8m

NasdaqGM:ARTV

US$289.0m

NasdaqGS:ADAP

US$212.3m

Price History & Performance

Recent News & Updates

Vaxart, Inc. Announces Initiation of Sentinel Cohort for Phase 2B Study Evaluating its Covid-19 Oral Pill Vaccine Candidate

New major risk - Financial position

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical Dysplasia

Consensus revenue estimates increase by 113%, EPS downgraded

There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Recent updates

Vaxart, Inc. Announces Initiation of Sentinel Cohort for Phase 2B Study Evaluating its Covid-19 Oral Pill Vaccine Candidate

New major risk - Financial position

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical Dysplasia

Consensus revenue estimates increase by 113%, EPS downgraded

There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Vaxart, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Vaxart Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Consensus revenue estimates increase by 865%

An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Vaxart, Inc. Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Price target increased by 11% to US$5.25

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Vaxart, Inc. to Report Q1, 2024 Results on May 13, 2024

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Now 27% overvalued after recent price rise

Vaxart, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Nasdaq Notifies Vaxart's Eligibility for an Additional 180-Day Compliance Period, or Until July 15, 2024, to Regain Compliance with the Bid Price Requirement

Vaxart, Inc. Announces CEO Changes

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Consensus revenue estimates increase by 57%

Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Market cap size

Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine Candidate

New major risk - Revenue and earnings growth

Vaxart, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Vaxart Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement

Vaxart, Inc. Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Vaxart, Inc.(NasdaqCM:VXRT) dropped from Russell 2000 Dynamic Index

New major risk - Share price stability

Vaxart, Inc. Announces Last Subject Dosed in Phase 2 Trial of Its Bivalent Norovirus Candidate, and All Subjects Challenge Study of Monovalent Norovirus Candidate

Consensus revenue estimates decrease by 60%, EPS upgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates upgraded to US$0.77 loss, revenue downgraded

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Vaxart, Inc. Doses First Subject in the Phase 2 Clinical Trial of Its Bivalent Norovirus Candidate

Vaxart, Inc. Names Phillip Lee as Chief Financial Officer

Price target decreased to US$7.75

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.23 loss per share (vs US$0.14 loss in 3Q 2021)

Vaxart, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Vaxart: The Market Still Isn't Buying Oral Vaccine Thesis

Vaxart, Inc. Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

Vaxart, Inc. Appoints Ray Stapleton as Chief Technology Officer

Ray Stapleton joins Vaxart as CTO

Vaxart, Inc. Announces Board Changes

Consensus revenue estimates fall by 12%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Vaxart, Inc. Appoints W. Mark Watson to Its Board of Directors

Price target decreased to US$9.75

Vaxart shareholders approve proposal to increase number of shares

Vaxart continues to lobby shareholders to vote to increase number of shares

Vaxart, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Vaxart, Inc. Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive